Sula Mazimba, MD and Kenneth Bilchick, MD
A recent single-center, retrospective study of hospitalized patients conducted by UVA Health School of Medicine researchers revealed that colchicine, which is commonly used to treat gout in heart failure, significantly improved survival rates for hospitalized heart failure patients.
Sula Mazimba, MD, MPH, an associate professor in the Department of Medicine’s Cardiovascular Division who specializes in heart failure, and Kenneth Bilchick, MD, MS, a professor of cardiovascular medicine, clinical investigator, and heart rhythm disorder specialist, are two of the researchers who initially conceived of and conducted the retrospective study. They’re now working on starting a randomized clinical trial to validate these findings.
Read more in the article “New Heart Failure Treatment in View” on the UVA Health Newsroom website.
For more about the colchicine study, read abstract in the journal Clinical Cardiology.